2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansKidney NeoplasmsMetastasectomyPrognosisRegistriesRetrospective StudiesSurvival RateConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersBlack or African AmericanCarcinoma, Renal CellHumansKidney NeoplasmsNeoplasm StagingNephrectomyRetrospective StudiesConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive margins
2021
Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act
Javier-DesLoges JF, Yuan J, Soliman S, Hakimi K, Meagher MF, Ghali F, Hsiang W, Patel DN, Kim SP, Murphy JD, Parsons JK, Derweesh IH. Evaluation of Insurance Coverage and Cancer Stage at Diagnosis Among Low-Income Adults With Renal Cell Carcinoma After Passage of the Patient Protection and Affordable Care Act. JAMA Network Open 2021, 4: e2116267. PMID: 34269808, PMCID: PMC8285737, DOI: 10.1001/jamanetworkopen.2021.16267.Peer-Reviewed Original ResearchConceptsLow-income patientsRenal cell carcinomaAffordable Care ActACA implementationNonexpansion statesLocalized diseaseAbsolute percentage changeCell carcinomaCancer stageExpansion statesNational Cancer DatabaseProportion of patientsRetrospective cohort analysisInsurance coveragePatient ProtectionCare ActMedicaid expansion statesInsurance coverage statusLow-income adultsEarly RCC detectionExpansion of insuranceSecondary outcomesInsurance statusAdjusted differenceCancer Database
2020
Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database
Patel DN, Ghali F, Meagher MF, Javier-Desloges J, Patel SH, Soliman S, Hakimi K, Yuan J, Murphy J, Derweesh IH. Utilization of renal mass biopsy in patients with localized renal cell carcinoma: A population-based study utilizing the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2020, 39: 79.e1-79.e8. PMID: 33160847, DOI: 10.1016/j.urolonc.2020.10.015.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiopsyCarcinoma, Renal CellDatabases, FactualFemaleHumansKidney NeoplasmsMaleMiddle AgedTumor BurdenUnited StatesConceptsUse of RMBRenal mass biopsyRenal cell carcinomaNational Cancer DatabaseCell carcinomaMultivariable analysisCancer DatabaseMass biopsyCharlson Comorbidity IndexCurrent guideline recommendationsYear of diagnosisPopulation-based studySmall renal massesComorbidity indexSurgical treatmentGuideline recommendationsTumor sizeRenal massesPersistent underutilizationPatientsCarcinomaStudy periodTumorsBiopsyHigh rateImpact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database
Ryan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.Peer-Reviewed Original ResearchConceptsPositive surgical marginsKaplan-Meier analysisRenal cell carcinomaNational Cancer DatabaseOverall survivalPartial nephrectomyMultivariable analysisSurgical marginsPathological stageCancer DatabaseCox regression multivariable analysisN0M0 renal cell carcinomaUS National Cancer DatabaseImpact of PSMRegression multivariable analysisPT3a diseaseCause mortalityMargin statusNegative marginsResection strategyCell carcinomaAggressive surveillanceRetrospective analysisKidney cancerPatientsRates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
Roussel E, Campi R, Larcher A, Verbiest A, Antonelli A, Palumbo C, Derweesh I, Ghali F, Bradshaw A, Meagher M, Heck M, Amiel T, Kriegmair M, Rubio J, Musquera M, D’Anna M, Autorino R, Guruli G, Veccia A, Linares-Espinos E, Van Bruwaene S, Hevia V, Porpiglia F, Checcucci E, Minervini A, Mari A, Pavan N, Claps F, Marchioni M, Capitanio U, Beuselinck B, Mir M, Albersen M, Group O. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. European Urology Oncology 2020, 3: 523-529. PMID: 32414697, DOI: 10.1016/j.euo.2020.04.006.Peer-Reviewed Original ResearchConceptsCytoreductive nephrectomyPostoperative complicationsMultivariable analysisMRCC patientsIntraoperative complicationsBlood lossSignificant predictorsComplex surgeryMetastatic renal cell carcinoma patientsHigher intraoperative blood lossHigh-grade postoperative complicationsMetastatic renal cell carcinomaRenal cell carcinoma patientsCase loadHigh-grade morbidityMultiple postoperative complicationsIntraoperative blood lossMetastatic renal cancerCell carcinoma patientsPrimary kidney tumorsRenal cell carcinomaLogistic regression analysisTherapy eraPerioperative complicationsPostoperative morbidityOncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansKidney NeoplasmsNeoplasm Recurrence, LocalNeoplasm StagingNephrectomyRetrospective StudiesTreatment OutcomeConceptsKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaRecurrence-free survivalRadical nephrectomyPartial nephrectomyOverall survivalMultivariable analysisCell carcinomaFunctional outcomeDe novo eGFRGlomular filtration rateClinical T stageMulticenter retrospective analysisRisk of recurrenceMulti-institutional analysisPT3a upstagingOncologic outcomesSecondary outcomesPrimary outcomeIndependent predictorsSurvival outcomesT stagePositive marginsPredictive factors
2019
Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria
Hamilton Z, Capitanio U, Pruthi D, Ghali F, Larcher A, Patel D, Eldefrawy A, Patel S, Cotta B, Bradshaw A, Meagher M, Miller N, Carenzi C, Wan F, Liss M, McGregor T, Montorsi F, Derweesh I. Risk Factors for Upstaging, Recurrence, and Mortality in Clinical T1-2 Renal Cell Carcinoma Patients Upstaged to pT3a Disease: An International Analysis Utilizing the 8th Edition of the Tumor-Node-Metastasis Staging Criteria. Urology 2019, 138: 60-68. PMID: 31836465, DOI: 10.1016/j.urology.2019.11.036.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRisk of recurrenceRenal cell carcinomaKaplan-Meier analysisHigher clinical stageClinical stageOverall survivalMultivariable analysisPT3a upstagingRisk factorsTumor-NodeT3a renal cell carcinomaRenal cell carcinoma patientsRisk of upstagingCell carcinoma patientsMulticenter retrospective analysisPerinephric fat invasionInitial clinical stageRenal vein invasionType of surgeryPT3a diseaseCarcinoma patientsPrimary outcomeFat invasionRenal vein